A number of other research analysts have also recently issued reports on the company. BidaskClub cut Syndax Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, April 11th. ValuEngine raised Syndax Pharmaceuticals from a strong sell rating to a sell rating in a report on Tuesday, March 20th. Morgan Stanley cut their price objective on Syndax Pharmaceuticals from $25.00 to $24.00 and set an overweight rating for the company in a report on Wednesday, March 14th. Zacks Investment Research cut Syndax Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, January 23rd. Finally, B. Riley reissued a buy rating and set a $40.00 price objective on shares of Syndax Pharmaceuticals in a report on Thursday, January 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. Syndax Pharmaceuticals currently has an average rating of Buy and a consensus price target of $23.86.
Shares of NASDAQ SNDX opened at $10.76 on Friday. The firm has a market cap of $282.05, a price-to-earnings ratio of -3.71 and a beta of 1.04. Syndax Pharmaceuticals has a 52-week low of $7.41 and a 52-week high of $15.43.
Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Monday, March 5th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.76) by ($0.04). The company had revenue of $1.19 million for the quarter, compared to the consensus estimate of $0.75 million. Syndax Pharmaceuticals had a negative net margin of 2,884.34% and a negative return on equity of 63.51%. Syndax Pharmaceuticals’s revenue was up 290.2% compared to the same quarter last year. equities research analysts anticipate that Syndax Pharmaceuticals will post -3.52 EPS for the current year.
In related news, insider Peter Ordentlich sold 7,500 shares of Syndax Pharmaceuticals stock in a transaction dated Tuesday, April 3rd. The stock was sold at an average price of $15.00, for a total value of $112,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 24.10% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. HighPoint Advisor Group LLC bought a new position in shares of Syndax Pharmaceuticals in the fourth quarter valued at about $102,000. Paloma Partners Management Co bought a new position in shares of Syndax Pharmaceuticals in the fourth quarter valued at about $144,000. California State Teachers Retirement System raised its holdings in shares of Syndax Pharmaceuticals by 60.9% in the second quarter. California State Teachers Retirement System now owns 15,587 shares of the company’s stock valued at $218,000 after buying an additional 5,900 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Syndax Pharmaceuticals in the fourth quarter valued at about $225,000. Finally, Alps Advisors Inc. raised its holdings in shares of Syndax Pharmaceuticals by 23.5% in the fourth quarter. Alps Advisors Inc. now owns 27,026 shares of the company’s stock valued at $237,000 after buying an additional 5,143 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This news story was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2018/04/17/syndax-pharmaceuticals-sndx-rating-lowered-to-d-at-thestreet.html.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.